Shares of Benitec Biopharma Inc. (NASDAQ:BNTC - Get Free Report) have been given a consensus rating of "Buy" by the six ratings firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $22.60.
Several equities analysts recently issued reports on the company. JMP Securities boosted their price target on Benitec Biopharma from $16.00 to $18.00 and gave the company a "market outperform" rating in a research note on Monday, October 14th. Leerink Partnrs upgraded Benitec Biopharma to a "strong-buy" rating in a research report on Monday, July 22nd. Oppenheimer initiated coverage on Benitec Biopharma in a research report on Wednesday, October 16th. They issued an "outperform" rating and a $35.00 target price for the company. Guggenheim began coverage on shares of Benitec Biopharma in a report on Thursday, September 12th. They issued a "buy" rating and a $17.00 price target on the stock. Finally, Piper Sandler restated an "overweight" rating on shares of Benitec Biopharma in a research note on Friday, October 18th.
Get Our Latest Stock Analysis on Benitec Biopharma
Institutional Investors Weigh In On Benitec Biopharma
Several large investors have recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new position in Benitec Biopharma in the second quarter worth $5,881,000. Janus Henderson Group PLC lifted its position in Benitec Biopharma by 35.5% during the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company's stock worth $1,266,000 after buying an additional 64,092 shares in the last quarter. Simplify Asset Management Inc. increased its position in Benitec Biopharma by 127.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 116,535 shares of the biotechnology company's stock valued at $1,071,000 after acquiring an additional 65,319 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company's stock worth $60,000 after purchasing an additional 1,102 shares in the last quarter. Institutional investors own 52.19% of the company's stock.
Benitec Biopharma Price Performance
Benitec Biopharma stock traded down $0.18 during mid-day trading on Friday, reaching $10.58. The company had a trading volume of 24,418 shares, compared to its average volume of 37,023. The company has a 50 day moving average of $9.74 and a 200-day moving average of $8.94. Benitec Biopharma has a 52 week low of $2.69 and a 52 week high of $12.89.
About Benitec Biopharma
(
Get Free ReportBenitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
Further Reading
Before you consider Benitec Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Benitec Biopharma wasn't on the list.
While Benitec Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
